Comparative Pharmacology
Head-to-head clinical analysis: CARDIZEM CD versus DYNACIRC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CARDIZEM CD versus DYNACIRC.
CARDIZEM CD vs DYNACIRC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Diltiazem is a calcium channel blocker that inhibits calcium ion influx across cardiac and vascular smooth muscle cell membranes, resulting in dilation of coronary arteries and peripheral arterioles, and decreased myocardial contractility and conduction velocity.
Dynacirc (isradipine) is a dihydropyridine calcium channel blocker that inhibits the influx of calcium ions through L-type calcium channels in vascular smooth muscle and cardiac muscle, leading to vasodilation and reduced peripheral vascular resistance, thereby lowering blood pressure.
Hypertension: 180-360 mg once daily orally. Angina: 120-360 mg once daily orally. Maximum dose: 480 mg/day.
2.5-10 mg orally once daily; titrate based on response. Maximum 20 mg/day.
None Documented
None Documented
Terminal elimination half-life: 6-8 hours (single dose), prolonged to 10-15 hours with multiple dosing or in elderly/hepatic impairment. Clinical context: Therapeutic steady-state achieved in 2-4 days.
Terminal elimination half-life is 7-8 hours. In elderly patients or those with hepatic impairment, half-life may be prolonged up to 14 hours, necessitating dose adjustment.
Renal: ~2-4% (unchanged), Hepatic metabolism to multiple metabolites; ~65% renal (metabolites), ~35% fecal/biliary. Total clearance: 5-7 mL/kg/min.
Primarily hepatic metabolism (CYP3A4) with <1% excreted unchanged in urine; approximately 60% of metabolites are excreted in feces via bile, and 35% in urine.
Category C
Category C
Calcium Channel Blocker
Calcium Channel Blocker